Glioblastoma Multiforme Epidemiology Insights
Glioblastoma Multiforme (GBM) Insights and Trends
- According to DelveInsight’s analysis, the total prevalent cases of GBM were ~38,000 in the 7MM (the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan) in 2025.
- The total number of incident cases of GBM in the United States was nearly 15,500 in 2025.
- In 2025, BRAF V600E mutation cases accounted for the largest share of incident GBM cases in the United States.
- The total number of cases of Primary GBM was found to be the highest than Secondary GBM in the United States and was estimated to be nearly 14,000 in 2025.
- GBM is associated with a higher disease burden in men than in women. Roughly 60% of the total GBM cases in the United States are men.
Glioblastoma Multiforme (GBM) Epidemiology Forecast in the 7MM
- 2025 Incident Cases of GBM: ~38,000
- GBM Growth Rate (2026–2036): 2.7% CAGR
DelveInsight's ‘Glioblastoma Multiforme Epidemiology Forecast – 2036’ report delivers an in-depth understanding of the GBM, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
|
Study Period
|
2022–2036
|
|
Historical Year
|
2022–2025
|
|
Forecast Period
|
2026–2036
|
|
Base Year
|
2026
|
|
Geographies Covered
|
ü North America : The US;
ü Europe: Germany, France, Italy, and Spain and the UK;
ü Asia-Pacific: Japan
|
|
GBM Epidemiology CAGR
(Study period/Forecast period)
|
2.7% (2026-2036)
|
|
GBM Epidemiology Segmentation Analysis
|
Patient Burden Assesment
· Total Incident Cases of GBM
· Gender-specific Incident Cases of GBM
· Type-specific Incident Cases of GBM
· Incident Cases based on Primary Site of GBM
· Age-specific Incident Cases of GBM
· Incident Cases based on Histologic Classification of GBM
· Unmethylation of the MGMT Gene Promoter Cases
· BRAF V600E Mutation Cases in GBM
· Line-wise Treated Pool of GBM
|
Glioblastoma Multiforme (GBM) Understanding and Diagnosis Algorithm
GBM Overview
GBM is often located in a region of the forebrain known as the cerebrum, which controls some of the most advanced processes such as speech and emotions. While GBM is highly locally invasive (invading normal brain tissue), it rarely spreads to other organs beyond the brain. A highly aggressive, fast-growing cancer, and treatment is often limited by the tumor location and the ability of a patient to tolerate surgery. Consequently, it is a particularly difficult cancer to treat. GBM may develop due to abnormal changes in the structure and orientation of cells secondary to oncogenes or the loss of tumor suppressor genes.
GBM Diagnosis
A patient with any neurological symptoms will first be given a physical exam that includes neurologic function tests (reflexes, muscle strength, eye and mouth movement, coordination, and alertness). If a tumor is suspected, the patient will have imaging tests so that doctors can look into the brain for any abnormality. Procedures that can be used for this purpose include MRI, CT, and MR spectroscopy. Surgical biopsy is also used for the diagnosis of GBM.
Further details are provided in the report...
Glioblastoma Multiforme (GBM) Epidemiology
Key Findings from GBM Epidemiological Analysis and Forecast
- According to DelveInsight’s estimates, the total number of incident cases of GBM in the 7MM was nearly 38,000 cases in 2025 and is projected to increase during the forecasted period.
- The total number of incident cases of GBM in the United States was nearly 15,500 in 2025.
- In 2025, BRAF V600E mutation cases accounted for the largest share of incident GBM cases in the United States.
- The total number of cases of Primary GBM was found to be the highest than Secondary GBM in the United States and was estimated to be nearly 14,000 in 2025.
- GBM is associated with a higher disease burden in men than in women. Roughly 60% of the total GBM cases in the United States are men.
Scope of the Glioblastoma Multiforme Report
- The report covers a segment of an executive summary, a descriptive overview of GBM, explaining its causes, signs and symptoms, and pathogenesis.
- Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.
Report Insights
- GBM patient population forecast
Report Key Strengths
- Epidemiology‑based (epi‑based) bottom‑up forecasting
- 11-year forecast
- Patient burden trends (by geography)
FAQs Related to Glioblastoma Multiforme Report
- What are the disease risks, burdens, and unmet needs of GBM? What will be the growth opportunities across the 7MM concerning the patient population with GBM?
- What is the historical and forecasted GBM patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
Reasons to Buy Glioblastoma Multiforme Epidemiology Report:
- Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
- To understand key opinion leaders’ perspectives around the diagnostic challenges to overcome barriers in the future.
- Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.
1 Key Insights
2 Report Introduction
3 Executive Summary of GBM
4 Epidemiology Forecast Methodology
5 GBM Epidemiology Overview at a Glance
5.1 Patient Share (%) Distribution by Country in 2025 in the 7MM
5.2 Patient Share (%) Distribution by Country in 2036 in the 7MM
6 Disease Background and Overview
6.1 Introduction
6.2 Structure and Mechanism of GBM
6.3 Glioblastoma Types
6.4 Risk Factors Associated With GBM
6.5 Diagnosis
6.5.1 Biomarker Testing for GBM
6.5.2 Diagnosis Algorithm of GBM
6.5.3 Diagnosis Guidelines
7 Epidemiology and Patient Population
7.1 Key Findings
7.2 Assumptions and Rationale
7.3 Total Incident Cases of GBM in the 7MM
7.4 The US
7.4.1 Total Incident Cases of GBM in the US
7.4.2 Gender-specific Incident Cases of GBM in the US
7.4.3 Type-specific Incident Cases of GBM in the US
7.4.4 Incident Cases based on Primary Site of GBM in the US
7.4.5 Age-specific Incident Cases of GBM in the US
7.4.6 Incident Cases based on Histologic Classification of GBM in the US
7.4.7 Unmethylation of the MGMT Gene Promoter Cases in the US
7.4.8 BRAF V600E Mutation Cases in GBM in the US
7.4.9 Line-wise Treated Pool of GBM in the US
7.5 EU4 and the UK
7.5.1 Total Incident Cases of GBM in EU4 and the UK
7.5.2 Gender-specific Incident Cases of GBM in EU4 and the UK
7.5.3 Type-specific Incident Cases of GBM in EU4 and the UK
7.5.4 Incident Cases based on Primary Site of GBM in EU4 and the UK
7.5.5 Age-specific Incident Cases of GBM in EU4 and the UK
7.5.6 Incident Cases based on Histologic Classification of GBM in EU4 and the UK
7.5.7 Unmethylation of the MGMT Gene Promoter Cases in EU4 and the UK
7.5.8 BRAF V600E Mutation Cases in GBM in EU4 and the UK
7.5.9 Line-wise Treated Pool of GBM in EU4 and the UK
7.6 Japan
7.6.1 Total Incident Cases of GBM in Japan
7.6.2 Gender-specific Incident Cases of GBM in Japan
7.6.3 Type-specific Incident Cases of GBM in Japan
7.6.4 Incident Cases based on Primary Site of GBM in Japan
7.6.5 Age-specific Incident Cases of GBM in Japan
7.6.6 Incident Cases based on Histologic Classification of GBM in Japan
7.6.7 Unmethylation of the MGMT Gene Promoter Cases in Japan
7.6.8 BRAF V600E Mutation Cases in GBM in Japan
7.6.9 Line-wise Treated Pool of GBM in Japan
7.6.3 Type-specific Incident Cases of GBM in Japan
8 Appendix
8.1 Bibliography
8.2 Report Methodology
9 DelveInsight Capabilities
10 Disclaimer
11 About DelveInsight
List of Tables:
Table 1 Summary of GBM Market and Epidemiology (2022–2036)
Table 2 Glioma Grading Scale
Table 3 Grading Within Types
Table 4 Circumscribed Glioma
Table 5 ESTRO-EANO GBM target delineation guideline
Table 6 Summary of Recommendations for SEOM
Table 7 Total Incident Patient Population of GBM in the 7MM (2022–2036)
Table 8 Total Incident Population of GBM in the US (2022–2036)
Table 9 Gender-specific Incident Cases of GBM in the US (2022–2036)
Table 10 Type-specific Incident Cases of GBM in the US (2022–2036)
Table 11 Incident Cases based on Primary Site of GBM in the US (2022–2036)
Table 12 Age-specific Incident Cases of GBM in the US (2022–2036)
Table 13 Incident Cases Based on Histologic Classification of GBM Tumor in the US (2022–2036)
Table 14 Unmethylation of the MGMT Gene Promoter Cases in the US (2022–2036)
Table 15 BRAF V600E Mutation Cases in the US (2022–2036)
Table 16 Line-wise Treated Pool of GBM in the US (2022–2036)
Table 17 Total Incident Patient Population of GBM in EU4 and the UK (2022–2036)
Table 18 Gender-specific Incident Cases of GBM in EU4 and the UK (2022–2036)
Table 19 Type-specific Incident Cases of GBM in EU4 and the UK (2022–2036)
Table 20 Incident Cases based on Primary Site of GBM in EU4 and the UK (2022–2036)
Table 21 Age-specific Incident Cases of GBM in EU4 and the UK (2022–2036)
Table 22 Incident Cases Based on Histologic Classification of GBM Tumor in EU4 and the UK (2022–2036)
Table 23 Unmethylation of the MGMT Gene Promoter Cases in EU4 and the UK (2022–2036)
Table 24 BRAF V600E Mutation Cases in EU4 and the UK (2022–2036)
Table 25 Line-wise Treated Pool of GBM in EU4 and the UK (2022–2036)
Table 26 Total Incident Population of GBM in Japan (2022–2036)
Table 27 Gender-specific Incident Cases of GBM in Japan (2022–2036)
Table 28 Type-specific Incident Cases of GBM in Japan (2022–2036)
Table 29 Incident Cases based on Primary Site of GBM in the US (2022–2036)
Table 30 Age-specific Incident Cases of GBM in Japan (2022–2036)
Table 31 Incident Cases Based on Histologic Classification of GBM Tumor in Japan (2022–2036)
Table 32 Unmethylation of the MGMT Gene Promoter Cases in Japan (2022–2036)
Table 33 BRAF V600E Mutation Cases in Japan (2022–2036)
Table 34 Line-wise Treated Pool of GBM in Japan (2022–2036)
List of Figures:
Figure 1 Mechanism of Action of GBM
Figure 2 Types of GBM Mutation in GBM
Figure 3 Risk Factors Associated With GBM
Figure 4 Tumor Biomarker Testing Rate
Figure 5 Total Incident Cases of GBM in the 7MM (2022–2036)
Figure 6 Total Incident Population of GBM in the US (2022–2036)
Figure 7 Gender-specific Incident Cases of GBM in the US (2022–2036)
Figure 8 Type-specific Incident Cases of GBM in the US (2022–2036)
Figure 9 Incident Cases based on Primary Site of GBM in the US (2022–2036)
Figure 10 Age-specific Incident Cases of GBM in the US (2022–2036)
Figure 11 Incident Cases Based on Histologic Classification of GBM Tumor in the US (2022–2036)
Figure 12 Unmethylation of the MGMT Gene Promoter Cases in the US (2022–2036)
Figure 13 BRAF V600E Mutation Cases in the US (2022–2036)
Figure 14 Line-wise Treated Pool of GBM in the US (2022–2036)
Figure 15 Total Incident Cases of GBM in EU4 and the UK (2022–2036)
Figure 16 Gender-specific Incident Cases of GBM in EU4 and the UK (2022–2036)
Figure 17 Type-specific Incident Cases of GBM in EU4 and the UK (2022–2036)
Figure 18 Incident Cases based on Primary Site of GBM in EU4 and the UK (2022–2036)
Figure 19 Age-specific Incident Cases of GBM in EU4 and the UK (2022–2036)
Figure 20 Incident Cases Based on Histologic Classification of GBM Tumor in EU4 and the UK (2022–2036)
Figure 21 Unmethylation of the MGMT Gene Promoter Cases in EU4 and the UK (2022–2036)
Figure 22 BRAF V600E Mutation Cases in EU4 and the UK (2022–2036)
Figure 23 Line-wise Treated Pool of GBM in EU4 and the UK (2022–2036)
Figure 24 Total Incident Population of GBM in Japan (2022–2036)
Figure 25 Gender-specific Incident Cases of GBM in Japan (2022–2036)
Figure 26 Type-specific Incident Cases of GBM in Japan (2022–2036)
Figure 27 Incident Cases based on Primary Site of GBM in Japan (2022–2036)
Figure 28 Age-specific Incident Cases of GBM in Japan (2022–2036)
Figure 29 Incident Cases Based on Histologic Classification of GBM Tumor in Japan (2022–2036)
Figure 30 Unmethylation of the MGMT Gene Promoter Cases in Japan (2022–2036)
Figure 31 BRAF V600E Mutation Cases in Japan (2022–2036)
Figure 32 Line-wise Treated Pool of GBM in Japan (2022–2036)
-pipeline.png&w=256&q=75)
